Loading…
No business profile yet.
Size 6467 (6467.TW) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $322M, the 624th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$235.00 on 6 Nov 2026.
Growth The operating margin is -2,617.6% (peer median 5.0%).
Valuation It trades at 1,229.5× enterprise value to sales against a peer median of 3.1× (most expensive of 20).
Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | NT$8.41M | NT$0 | NT$1.07M | NT$6.36M |
| Revenue growth | — | — | -100% | -83% | — |
| Gross profit | n/a | -NT$2.08M | -NT$6.99M | -NT$7.82M | -NT$3.88M |
| EBITDA | n/a | -NT$211M | -NT$163M | -NT$113M | -NT$57.8M |
| Net income | n/a | -NT$214M | -NT$167M | -NT$121M | -NT$66.3M |
| Free cash flow | n/a | -NT$209M | -NT$166M | -NT$107M | -NT$63.6M |
| Capital expenditure | n/a | NT$6.31M | NT$8.82M | NT$2.89M | NT$829,000 |
| Total debt | NT$8.56M | NT$11.3M | NT$16.7M | NT$53.6M | NT$32.0M |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6467.TW | Peer median | Rank in peer set |
|---|---|---|---|
| Operating margin | -2,617.6% | 5.0% | lowest of 20 |
| EV / Sales | 1,229.5× | 3.1× | most expensive of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| 6467 6467.TW | Taiwan | $322M | n/a | n/a | -2,618% | 1,229.5× | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $321M | +149% | +66% | 9% | 3.5× | n/a | n/a |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $322M | -21% | -32% | -58% | 5.0× | 2.5% | -4.9% |
| Enanta Pharmaceuticals ENTA | United States | $320M | -28% | +1% | -90% | 4.8× | n/a | n/a |
| Solara Active Pharma Sciences SOLARA.NS | India | $323M | +23% | +27% | 8% | 2.3× | 37.7% | -3.2% |
| Eikon Therapeutics EIKN | United States | $320M | -41% | n/a | n/a | n/a | n/a | n/a |
| GC Corp. 005250.KS | South Korea | $319M | -32% | +10% | 1% | 1.2× | 31.5% | +7.4% |
| Shandong Sito Bio-technology 300583.SZ | China | $318M | -26% | +19% | 6% | 2.5× | 2.7% | +2.3% |
| Zhejiang Shengda Bio-Pharm 603079.SS | China | $318M | -29% | -3% | 7% | 2.5× | 5.7% | -0.3% |
| Enwei Pharmaceutical 301331.SZ | China | $326M | -20% | -7% | 5% | 2.3× | 15.1% | +7.3% |
| Kitazato 368A.T | Japan | $317M | -9% | +9% | 52% | 3.1× | -16.7% | +5.4% |
| Hangzhou Tianmushan Pharmaceutical Enterprise 600671.SS | China | $327M | -10% | -19% | 5% | 11.5× | 22.5% | +0.5% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $328M | -38% | +10% | -8% | 6.2× | n/a | n/a |
| Swedencare SECARE.ST | Sweden | $315M | -23% | +3% | 7% | 1.7× | 5.5% | +62.1% |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | 0% | +3% | 21% | 1.8× | -10.4% | +10.3% |
| Ocugen OCGN | United States | $314M | -39% | -11% | -1,444% | 66.5× | n/a | n/a |
| Honz Pharmaceutical 300086.SZ | China | $330M | -35% | -23% | -54% | 7.9× | 58.0% | -12.8% |
| Zhejiang Zhenyuan Share 000705.SZ | China | $312M | -25% | -33% | -5% | 1.1× | n/a | n/a |
| Emergent BioSolutions EBS | United States | $312M | -27% | -18% | 5% | 1.0× | -0.1% | -13.7% |
| Chengdu Huasun Technology 000790.SZ | China | $333M | -22% | -36% | -57% | 5.9× | 28.5% | -6.4% |
| Shanxi C&Y Pharmaceutical 300254.SZ | China | $308M | -44% | -6% | 9% | 3.3× | 10.1% | +0.6% |